Neurobiological Technologies(OTC) NTII

Neurobiological Technologies, Inc. is a biotechnology company that has shifted its focus towards liquidation and dissolution, a plan endorsed by stockholders in 2009. Established in 1987, the company was previously dedicated to developing pharmaceutical treatments for various human ailments.

Products and Services

• Formerly focused on experimental pharmaceutical treatments
• Engaged in research and development in the biotechnology sector
• Currently in the process of liquidation

Growth Outlook

• Company has a significant cash position of $9.58 million as of September 2009
• Current ratio stands at an impressive 35.34, indicating strong liquidity
• Net income of $5.41 million reported in the latest quarter

Financial Highlights

• Revenue of $6.03 million in the most recent quarter
• Net profit margin of 89.69% reflects operational efficiency
• Cash and short-term investments total $26.49 million

Neurobiological Technologies, Inc. has undergone significant changes since its inception, transitioning from a research-focused entity to a company in liquidation. The financial data indicates a strong cash position, which may provide a buffer during the dissolution process. The impressive current ratio suggests that the company can meet its short-term obligations effectively. Despite the challenges faced, the recent net income and revenue figures highlight the operational efficiency that has been maintained. Investors may find the company's financial health and liquidity position noteworthy as it navigates its current phase.